Warfarin Initiation with Interacting Antibiotic and NSAID
A 68-year-old man (weight 72 kg, serum creatinine 1.3 mg/dL, CrCl ~52 mL/min) is admitted with a deep vein thrombosis. He is started on warfarin 5 mg PO daily and enoxaparin bridging. His home medications are amiodarone 200 mg daily (long-standing), atorvastatin 20 mg, and metoprolol. On day 3 the team adds trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection and ibuprofen 400 mg q8h for knee pain. His INR on day 4 is 1.6; on day 6 it is 4.9 with no bleeding. The resident asks whether to give vitamin K and how to adjust therapy.
1. Identify the interacting drugs and explain the pharmacologic mechanisms by which each could raise this patient's INR.
Read the worked answer
TMP-SMX: the trimethoprim component inhibits CYP2C9 (S-warfarin metabolism) and sulfamethoxazole can displace warfarin from albumin and may reduce vitamin K-producing gut flora - a triple hit; TMP-SMX is a classic potent potentiator of warfarin effect. Ibuprofen: NSAIDs inhibit platelet cyclooxygenase (additive bleeding risk independent of INR) and can displace protein-bound warfarin; they also cause GI mucosal injury. Amiodarone: already on board - inhibits CYP2C9/CYP3A4 and has a very long half-life, so its effect accumulates for weeks; it slows warfarin clearance and is a persistent confounder here. Atorvastatin is a minor contributor (metabolized by CYP3A4, little effect on INR). Net: two new interacting drugs plus a long-acting CYP2C9 inhibitor explain the jump from 1.6 to 4.9.
2. The patient is asymptomatic with INR 4.9. Decide whether to give vitamin K, and justify using guideline thresholds.
Read the worked answer
For an asymptomatic patient with INR 4.5–10 and no bleeding, routine vitamin K is not recommended - it does not reduce bleeding and can cause warfarin resistance and rebound thrombosis. Recommended action: hold warfarin, remove the offending drugs if possible (stop ibuprofen; consider an alternative antibiotic such as nitrofurantoin or cephalexin if susceptible), recheck INR in 24–48 h, and resume at a reduced dose once INR is in range. Reserve oral vitamin K (1–2.5 mg) for INR >10, or for high bleeding risk/active bleeding (then use 5–10 mg IV plus PCC for major bleeding). Because amiodarone is co-administered, expect a prolonged warfarin dose reduction need - the amiodarone effect persists for weeks, so plan a lower maintenance dose and frequent INR checks.
3. Outline a monitoring and dose-adjustment plan for the next 2 weeks, including what to tell the patient about the NSAID.
Read the worked answer
- Stop ibuprofen; if analgesia needed, use acetaminophen (≤2–3 g/day) with awareness of minor INR effects, or a short course of a non-NSAID. 2) Hold warfarin 1–2 days; recheck INR daily until trending down, then every 2–3 days. 3) When INR <3, restart warfarin at a reduced dose (e.g., 2.5–3 mg/day given amiodarone co-therapy) and titrate to INR 2–3. 4) Continue enoxaparin bridge until INR ≥2 on two consecutive days and total ≥5 days of overlap. 5) Counsel: avoid all NSAIDs (including OTC ibuprofen/naproxen), avoid alcohol binges, report black stools/bruising/headache, maintain consistent vitamin K intake (leafy greens), and inform every prescriber that they take warfarin. 6) Recheck INR at least weekly for 2–4 weeks because amiodarone's enzyme inhibition persists.